Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian firm reports 17.95 billion rupees ($460 million) in sales, up from 17.08 billion rupees a year ago, with a 2012 goal of being a top-five generics company.